| 名稱 | KI8751 |
| 描述 | KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM. |
| 細胞實驗 | To evaluate the inhibition of VEGF-Stimulated HUVEC proliferation by Ki8751, HUVECs are plated at a density of 4000 cells/200 μL/well in a type I collagen pre-coated 96-well plates. After 24 hours, the cells are incubated for 1 hour with Ki8751 and then stimulated with 20 ng/mL rhVEGF. The cultures are incubated at 37 °C for 72 hours, then pulsed with 1 μCi/well [3H]thymidine and re-incubated for 14 hours. Cells are assayed for the incorporation of tritium using a beta counter. (Only for Reference) |
| 激酶實驗 | Cellular Kinase Assays: NIH3T3 cells prepared by transfection of human KDR. The cells are cultured in a collagen type I coated 96-well plate in an amount of 1.5 × 104 per well. The medium is then replaced by a DMEM medium containing 0.1% FCS. Ki8751 diluted in DMSO is added to each well and cultured. rhVEGF is added to a final concentration of 100 ng/mL, and the stimulation of cells is carried out at 37 °C. The cells are washed with PBS (pH 7.4), 50 μL of a solubilization buffer (20 mM HEPES (pH 7.4), 150 mM NaCl, 0.2% Triton X-100, 10% glycerol, 5 mM Na3VO4, 5 mM disodium ethylenediamine tetraacetate, and 2 mM Na4P2O7) is then added and a cell extract is prepared. Separately, PBS (50 μL, pH 7.4) containing 5 μg/mL of antiphosphotyrosine antibody (PY20) is added to a microplate for ELISA. After washing of the plate, 300 μL of a blocking solution is added. The cell extract is transferred to the plate. An anti-VEGFR2 antibody and a peroxidase-labeled anti-rabbit Ig antibody are added. Next, a chromophoric substrate for peroxidase is added, and the absorbance at 450 nm is measured with microplate reader. The VEGFR2 phosphorylation activity for each well is determined by presuming the absorbance with the addition of VEGF and without the addition of the test sample to be 100% VEGFR2 phosphorylation activity and VEGF to be 0% VEGFR2 phosphorylation activity. The concentration of the inhibition (%) of VEGFR2 Phosphorylation is determined for each case, and IC50 value is calculated. |
| 體外活性 | 在LC-6細胞的裸鼠異種移植模型中,Ki8751（5 mg/kg）在不影響體重的情況下完全抑制腫瘤生長.在攜帶人類腫瘤異種移植物GL07,St-4,LC6,DLD-1和A375細胞的裸鼠中,Ki8751（20 mg/kg）抑制腫瘤生長. |
| 體內(nèi)活性 | 在人臍靜脈內(nèi)皮細胞（HUVECs）中,Ki8751（1 nM-100 nM）有效降低VEGF刺激的細胞增殖和血管通透性。在轉(zhuǎn)移性結(jié)直腸癌（CRC）細胞MIP,RKO,SW620和SW480中,Ki8751（10 nM）增加細胞衰老,但在HCT116中無此效果。Ki8751有效且選擇性抑制VEGFR-2,IC50為0.9 nM。Ki8751也抑制PDGFRα,c-Kit和 FGFR-2,具有更高的IC50值為40 nM–170 nM。 |
| 存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 14 mg/mL (29.82 mM), Sonication is recommended.
|
| 關(guān)鍵字 | inhibit | KI-8751 | KI 8751 | Ki 8751 | KI8751 | Inhibitor | VEGFR | Vascular endothelial growth factor receptor |
| 相關(guān)產(chǎn)品 | Lapatinib | Neratinib | Gefitinib | Erlotinib | Osimertinib | Amlexanox | Gilteritinib | Formononetin | Ferulic Acid | Regorafenib | Pazopanib | Sorafenib |
| 相關(guān)庫 | 抑制劑庫 | 抗乳腺癌化合物庫 | 經(jīng)典已知活性庫 | 抗癌化合物庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 膜蛋白靶向化合物庫 | 酪氨酸激酶分子庫 | 共價抑制劑庫 | 細胞重編程化合物庫 |